ArticleThe Lancet. Global health2020
Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection.
Article in The Lancet. Global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 210 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
210 citing papers in PubMed, 2 syntheses or guidelines pooled it, 370 citations in OpenAlex.
- Epidemics, Lockdown Measures and Vulnerable Populations: A Mixed-Methods Systematic Review of the Evidence of Impacts on Mother and Child Health in Low-and Lower-Middle-Income Countries.International journal of health policy and management · 2022Pooled it
- The Impact of the COVID-19 Pandemic on Immunization Campaigns and Programs: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Oral health among HIV-positive and HIV-negative children in Phnom Penh, Cambodia: a cross-sectional study.BMJ paediatrics open · 2021Trial
- Routine immunization uptake and timeliness in young children exposed to multidrug-resistant tuberculosis: A secondary analysis of the Tuberculosis Child Multidrug-Resistant Preventive Therapy multi-site randomised controlled trial.BMC global and public health · 2026Article
- Exploring the drivers of low DPT3 vaccination coverage and the implications in rural, urban and peri-urban Uganda: a cross-sectional study of Hoima and Wakiso districts of Uganda.BMC public health · 2026Article
- The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.PLoS medicine · 2026Article
- Understanding barriers to immunization among women with zero-dose or under-immunized children in an urban area in Cameroon.Frontiers in public health · 2026Article
- Impact of COVID-19 Pandemic on Pediatrics Primary Healthcare Visits in a University Based Family and Community Medicine Center in Saudi Arabia.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2026Article
- The impact of the COVID-19 pandemic on HIV, malaria, tuberculosis and childhood vaccination services in Guinea: an interrupted time series analysis.BMJ global health · 2025Article
- Impact of the COVID-19 pandemic on the timeliness of pertussis-containing vaccination: A cohort study in Shanghai, China.Human vaccines & immunotherapeutics · 2025Article
- Impact of the COVID-19 Pandemic on Routine Childhood Vaccination Coverage in Ecuador From 2019 to 2021: Comparative Analysis.JMIRx med · 2025Article
- Modelling the relative contribution of infection, routine vaccination and supplementary immunisation activities to measles seroconversion in Kenyan Children.PLoS computational biology · 2025Article
- Article
- Sixth wave of global public health progress.One health (Amsterdam, Netherlands) · 2025Article
- Next-generation vaccines for influenza B virus: advancements and challenges.Archives of virology · 2025Review
- Effect of COVID-19 pandemic on well child follow-up visits and vaccination: A Single unit experience from Turkey.Pakistan journal of medical sciences · 2025Article
- Innovative and sustainable solutions for reducing 'zero-dose' vaccination: How can the region respond?Frontiers in public health · 2025Article
- Community pharmacists' knowledge, beliefs, and perceived barriers toward vaccination services at community pharmacies: A cross-sectional study from Saudi Arabia.Human vaccines & immunotherapeutics · 2024Article
- Article
- The impact of COVID-19 on routine child immunisation in South Africa.BMC public health · 2024Article
150 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundNational immunisation programmes globally are at risk of suspension due to the severe health system constraints and physical distancing measures in place to mitigate the ongoing COVID-19 pandemic. We aimed to compare the health benefits of sustaining routine childhood immunisation in Africa with the risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through visiting routine vaccination service delivery points.
methodsWe considered a high-impact scenario and a low-impact scenario to approximate the child deaths that could be caused by immunisation coverage reductions during COVID-19 outbreaks. In the high-impact scenario, we used previously reported country-specific child mortality impact estimates of childhood immunisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Streptococcus pneumoniae, rotavirus, measles, meningitis A, rubella, and yellow fever to approximate the future deaths averted before 5 years of age by routine childhood vaccination during a 6-month COVID-19 risk period without catch-up campaigns. In the low-impact scenario, we approximated the health benefits of sustaining routine childhood immunisation on only the child deaths averted from measles outbreaks during the COVID-19 risk period. We assumed that contact-reducing interventions flattened the outbreak curve during the COVID-19 risk period, that 60% of the population will have been infected by the end of that period, that children can be infected by either vaccinators or during transport, and that upon child infection the whole household will be infected. Country-specific household age structure estimates and age-dependent infection-fatality rates were applied to calculate the number of deaths attributable to the vaccination clinic visits. We present benefit-risk ratios for routine childhood immunisation, with 95% uncertainty intervals (UIs) from a probabilistic sensitivity analysis.
findingsIn the high-impact scenario, for every one excess COVID-19 death attributable to SARS-CoV-2 infections acquired during routine vaccination clinic visits, 84 (95% UI 14-267) deaths in children could be prevented by sustaining routine childhood immunisation in Africa. The benefit-risk ratio for the vaccinated children is 85 000 (4900-546 000), for their siblings (<20 years) is 75 000 (4400-483 000), for their parents or adult carers (aged 20-60 years) is 769 (148-2700), and for older adults (>60 years) is 96 (14-307). In the low-impact scenario that approximates the health benefits to only the child deaths averted from measles outbreaks, the benefit-risk ratio to the households of vaccinated children is 3 (0-10); if the risk to only the vaccinated children is considered, the benefit-risk ratio is 3000 (182-21 000).
interpretationThe deaths prevented by sustaining routine childhood immunisation in Africa outweigh the excess risk of COVID-19 deaths associated with vaccination clinic visits, especially for the vaccinated children. Routine childhood immunisation should be sustained in Africa as much as possible, while considering other factors such as logistical constraints, staff shortages, and reallocation of resources during the COVID-19 pandemic.
fundingGavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.